Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B

Pediatric Infectious Disease Journal

Volumn 22, Issue 6, 2003, Pages 567-569

  Zvulunov, Alex ^a,c   Cagnano, Emanuala ^b   Frankenburg, Shoshana ^d   Barenholz, Yehezkel ^d   Vardy, Daniel ^c  

^a Clalit Health Services   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Amphotericin B; Cutaneous leishmaniasis; Topical application

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; LESHCUTAN; PAROMOMYCIN; STIBOGLUCONATE SODIUM;

ARTICLE; CASE REPORT; CHILD; DRUG EFFICACY; HUMAN; LEISHMANIA; PERSISTENT INFECTION; PRIORITY JOURNAL; SIDE EFFECT; SKIN LEISHMANIASIS;

ADMINISTRATION, TOPICAL; AMPHOTERICIN B; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LEISHMANIASIS, CUTANEOUS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SOLUTIONS; TREATMENT OUTCOME;

EID: 0038539739     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200306000-00017     Document Type: Article

References (12)

1. El-On JL, Weinrauch R, Livshin Z, Even Paz, Jacobs GP. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methyl-benzethonium chloride. BMJ 1985;291:704-5.
2. Bensalah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-6.
3. Klaus S, Axelrod O, Jonas F, Frankenburg S. Changing patterns of cutaneous leishmaniasis in Israel. Trans R Soc Trop Med Hyg 1994;88:649-50.
4. Vardy D, Barenholz Y, Cohen R, et al. Topical amphotericin B for cutaneous leishmaniasis. Arch Dermatol 1999;135:856-7.
5. Vardy D, Barenholz Y, Naftoliev N, Klaus S, Gilead L, Frankenburg S. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc Trop Med Hyg 2001;95:1-3.
6. Klaus S, Frankenburg S. Cutaneous leishmaniasis in the Middle East. Clin Dermatol 1999;17:137-41.
7. Mehregan DR, Mehregan AH, Mehregan DA. Histologic diagnosis of cutaneous leishmaniasis. Clin Dermatol 1999;17:297-304.
8. Vardy D, Frankenburg S, Goldenhersh M, et al. Unusually extensive disease caused by Leishmania major parasites. Clin Exp Dermatol 1993;18:36-40.
9. Satti M, El-Hassan A, Al-Gindan Y, et al. Peripheral neural involvement in cutaneous leishmaniasis. Int J Dermatol 1989;28:243-7.
10. Vardy DA, Cohen A, Kachko L, Zvulunov A, Frankenburg S. Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous rheumatoid nodule. Br J Dermatol 1999;141:914-7.
11. Moskowitz PF, Kurban Ak. Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Clin Dermatol 1999;17:305-15.
12. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992;27:227-31.